BIOTRONIK and CardioFocus Partner to Expand Pulsed Field Ablation Access in Europe

Partnership Brings Centauri™ PFA System to 17 European Markets, Enhancing Treatment Options for Atrial Fibrillation

 

BIOTRONIK, a global leader in medical technology, today announced a strategic distribution agreement with CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias. BIOTRONIK will serve as the exclusive distributor of the Centauri™ Pulsed Field Ablation (PFA) System in selected European countries. 

This collaboration represents a significant milestone in the commercial expansion of Centauri — a next generation focal PFA system that provides physicians with highly controllable and versatile solution for cardiac ablation in the treatment of paroxysmal atrial fibrillation. Centauri stands out for its compatibility with widely used mapping systems, flexible workflow integration, and has an unmatched body of real-world evidence.  These features position Centauri as a frontrunner in the field of focal PFA. 

“We are proud to collaborate with CardioFocus to expand the reach of the Centauri System in key European markets,” said Dr. Andreas Hecker, President CRM/EP at BIOTRONIK. “As pulsed field ablation evolves, hospitals increasingly need solutions that combine strong clinical performance with flexibility. This collaboration reflects our ongoing commitment to advancing innovation in electrophysiology and supporting physicians in improving patient outcomes.” 

The Centauri System is CE-marked and has been used to treat over 8000 patients across Europe. Clinical experience reported in over 40 publications has demonstrated a high level of procedural efficiency, durable cardiac lesions, and a low rate of complications. 

“We are thrilled to partner with a company as well-established and clinically trusted as BIOTRONIK to bring our technology to more physicians and patients across Europe,” said Steve Ogilvie, CEO of CardioFocus. “BIOTRONIK’s deep electrophysiology expertise, expansive global presence, and commitment to physician training make them the ideal partner to support the next phase of Centauri’s growth.” 

This collaboration leverages BIOTRONIK’s global leadership in cardiac rhythm management and electrophysiology with CardioFocus’ pioneering approach. Together, BIOTRONIK and CardioFocus are committed to advancing atrial fibrillation care by combining innovative technology with a shared focus on physician education and patient-centered solutions.

 

 

Back